Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia, and Australia.
In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
Q4 and FY 2025 report
Sobi published its Q4 and FY 2025 report on 5 February 2026.
Acquisition of Arthrosi Therapeutics
Sobi hosted an investor conference call on 15 December about the acquisition of Arthrosi Therapeutics.
Loading...
Press releases
Upcoming events
Loading...